Current Highlight from June 27, 2014
The Issue of Low Dose from Mutagens
NCTR scientists, in collaboration with scientists from CDER, Swansea University (UK), and the National Institute for Public Health and the Environment (The Netherlands), have shown significant increases in the mutant frequency in gpt-delta mice treated with the model mutagen, ethyl methanesulfonate (Group 2B carcinogen), at doses below the previously reported No Genotoxic Effect Level. The gpt-delta transgenic mouse model has an extraordinarily low background mutant frequency and is better able to detect low-dose, small-magnitude responses than other in vivo mutation models, such as the Muta™Mouse, that have higher spontaneous mutant frequencies. This study, which provides guidance on factors important to accurately determining low-dose effects from mutagenic agents, was published in Environmental and Molecular Mutagenesis
as the Editor’s Choice.
as the Editor’s Choice.For additional information, please contact Xuefei Cao, Ph.D., Division of Genetic and Molecular Toxicology, or Robert H. Heflich, Ph.D., Director, Division of Genetic and Molecular Toxicology, FDA/NCTR.
NCTR Research Highlights Archives
Contact FDA
870-543-7000
National Center for Toxicological Research
Food and Drug Administration
3900 NCTR Road
Jefferson, AR 72079
No hay comentarios:
Publicar un comentario